Abstract:In this study, the effects of 17 CYP3A4 variants and drug-drug interactions (DDI) with its mechanism on alectinib metabolism were investigated. In vitro incubation systems of rat liver microsomes (RLM), human liver microsomes (HLM) and recombinant human CYP3A4 variants were established. The formers were used to screen potential drugs that inhibited alectinib metabolism and study the underlying mechanism, and the latter was used to determine the dynamic characteristics of CYP3A4 variants. Alectinib and its main metabolite M4 were quantitatively determined by ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). The results showed that compared with CYP3A4.1, only CYP3A4.29 showed higher catalytic activity, while the catalytic activity of CYP3A4.4, .7, .8, .12, .14, .16, .17, .18, .19, .20, .23, and .24 decreased significantly. Among them, the catalytic activity of CYP3A4.20 is the lowest, only 2.63% of that of CYP3A4.1. Based on the RLM incubation system in vitro, 81 drugs that may be combined with alectinib were screened, among which 18 drugs had an inhibition rate higher than 80%. In addition, nicardipine had an inhibition rate of 95.09% with a half-maximum inhibitory concentration (IC 50 ) value of 3.54 ± 0.96 μM in RLM and 1.52 ± 0.038 μM in HLM, respectively. There was a mixture of non-competitive and anti-competitive inhibition of alectinib metabolism in both RLM and HLM. In vivo experiments of Sprague–Dawley (SD) rats, compared with the control group (30 mg/kg alectinib alone), the AUC (0–t) , AUC (0–∞) , T max and C max of alectinib administered in combination with 6 mg/kg nicardipine were significantly increased in the experimental group. In conclusion, the metabolism of alectinib was affected by polymorphisms of the CYP3A4 gene and nicardipine. This study provides reference data for clinical individualized administration of alectinib in the future.

The effect of CYP3A4 genetic polymorphism and drug interaction on the metabolism of istradefylline

Drug Interaction of Nifedipine with Ginkgo Flavones in vitro

Study on the Effect of Three CYP2C9 Variants on Drug–Drug Interaction Related to Six Drugs in Vitro by LC–MS/MS Method

Effect of Cyp2d6 Genetic Polymorphism on the Metabolism of Citalopram in Vitro

Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism

Effects on CYP2D6 by the Single Use of Ampicillin and Shuanghuanglian or Combination of Both

The impacts of natural product miltirone and the CYP2D6 pharmacogenetic phenotype on fluoxetine metabolism

The Influence of CYP3A5*3 and BCRPC421A Genetic Polymorphisms on the Pharmacokinetics of Felodipine in Healthy Chinese Volunteers.

Effects of CYP2D6 Genetic Polymorphism and Drug Interaction on the Metabolism of Dacomitinib

Effect of CYP2C19 genetic polymorphism on drug metabolism and individualized therapy

Study on the Effects of Human CYP450 3A4 Allelic Polymorphism on Drug Metabolisms and Drug-Drug Interactions in Vitro

The Impacts of CYP3A4 Genetic Polymorphism and Drug Interactions on the Metabolism of Lurasidone

Functional Characterization of Five CYP2C8 Variants and Prediction of CYP2C8 Genotype-Dependent Effects on in Vitro and in Vivo Drug-Drug Interactions.

Functional evaluation of CYP2C19 and CYP3A4 gene polymorphism on ibuprofen metabolism

CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients

Effect of recombinant CYP3A4 variants and interaction on imatinib metabolism in vitro

Effect of CYP3A5*3 Polymorphism on Pharmacokinetic Drug Interaction Between Tacrolimus and Amlodipine

Effects of CYP2C93 and CYP2C913 on Diclofenac Metabolism and Inhibition-based Drug-Drug Interactions.

The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population

Effect of CYP2C9 Genetic Polymorphism on the Metabolism of Flurbiprofen in Vitro.

Functional Evaluation of Cyclosporine Metabolism by CYP3A4 Variants and Potential Drug Interactions.